An Open-Label, Multicenter 52-Week Study Assessing the Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes
收藏DataCite Commons2025-04-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007637/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
Primary Objective:
The primary objective of this study is to assess the overall safety of lixisenatide once
daily treatment in combination with background oral anti-diabetic treatment over 52 weeks in
patients with type 2 diabetes in Japan.
Secondary Objective:
To assess the effects of lixisenatide in combination with background oral antidiabetic drug
(OAD) on:
- HbA1c;
- Fasting plasma glucose;
- Body weight.
提供机构：
Vivli
创建时间：
2022-02-02
